Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $326,911.68 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,413 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total value of $326,911.68. Following the sale, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at $1,506,616.32. The trade was a 17.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $7.44 during trading on Friday, reaching $234.76. The stock had a trading volume of 887,560 shares, compared to its average volume of 933,246. The firm has a market capitalization of $15.07 billion, a price-to-earnings ratio of 79.85, a P/E/G ratio of 0.47 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 52 week low of $128.80 and a 52 week high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The stock has a fifty day simple moving average of $229.71 and a two-hundred day simple moving average of $217.40.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same quarter in the previous year, the business earned $8.13 EPS. The business’s revenue was up 10.4% on a year-over-year basis. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its position in Jazz Pharmaceuticals by 44.5% in the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after purchasing an additional 517,514 shares during the period. Tri Locum Partners LP bought a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $29,995,000. Bank of America Corp DE increased its holdings in Jazz Pharmaceuticals by 10.9% in the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after buying an additional 99,656 shares during the period. Amundi raised its stake in shares of Jazz Pharmaceuticals by 2,445.3% in the 1st quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock valued at $10,519,000 after buying an additional 53,454 shares in the last quarter. Finally, Rokos Capital Management LLP acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $9,833,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JAZZ has been the subject of several recent analyst reports. Wells Fargo & Company increased their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 price target on Jazz Pharmaceuticals in a report on Wednesday, August 26th. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $293.45.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.